| abstract |
This invention relates to a novel benzopyran and other benzo-condensed leukotriene (LTB4) B4 antagonists and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds, and to a method of using such compounds as LBT4 antagonists. The compounds of this invention inhibit the action of LTB4 and are therefore useful in the treatment of LBT4-induced diseases, such as inflammatory disorders, including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, psoriasis, and other skin disorders such such as eczema, erythema, pruritus and acne, stroke and other forms of reperfusion ailments, graft rejection, autoimmune diseases, asthma and other conditions in which a noticeable neutrophil infiltration occurs. |